Search Results

MaxCyte, Inc. today announced the signing of a strategic platform license (SPL).

Lion TCR Pte Ltd, clinical-stage biotech company specialized in the development and commercialization of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers, has been recognized as the ‘Most Promising Cell & Gene Therapy Startup in Asia’ category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022, organized by IMAPAC.

Anocca AB and Shinobi Therapeutics announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies for solid tumors.

Xcell Biosciences Inc. and AmplifyBio today announced the launch of a partnership designed to streamline and improve the manufacturing process for engineered T-cell receptor (TCR) therapies targeting solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland.